Should I buy or sell Galapagos stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares. View GLPG analyst ratings or view top-rated stocks .

What is Galapagos' stock price target for 2024?

5 analysts have issued 12-month target prices for Galapagos' stock. Their GLPG share price targets range from $31.00 to $38.00. On average, they predict the company's stock price to reach $34.50 in the next year. This suggests a possible upside of 19.5% from the stock's current price. View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts .

How have GLPG shares performed in 2024?

Galapagos' stock was trading at $40.65 at the beginning of 2024. Since then, GLPG stock has decreased by 29.0% and is now trading at $28.86. View the best growth stocks for 2024 here .

When is Galapagos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GLPG earnings forecast .

What ETFs hold Galapagos' stock?

ETFs with the largest weight of Galapagos (NASDAQ:GLPG) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) . ERShares NextGen Entrepreneurs ETF (ERSX) .

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com . Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD) , Celyad Oncology (CYAD) , Intercept Pharmaceuticals (ICPT) , NVIDIA (NVDA) , argenx (ARGX) , AbbVie (ABBV) , Biogen (BIIB) , Pharming Group (PHGUF) , Trade Desk (TTD) and Collegium Pharmaceutical (COLL) .

When did Galapagos IPO?

Galapagos (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who are Galapagos' major shareholders?

Galapagos' stock is owned by a variety of retail and institutional investors. Top institutional investors include GAMMA Investing LLC (0.00%).

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLPG

Galapagos (GLPG) Stock Price, News & Analysis

→ Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad)

Free GLPG Stock Alerts

$28.95

+0.04 (+0.14%)

(As of 12:11 PM ET)

Compare

Today's Range: $28.82
▼
$29.13
50-Day Range: $28.91
▼
$39.71
52-Week Range: $28.82
▼
$45.21

Volume: 32,666 shs
Average Volume: 128,696 shs
Market Capitalization: $1.91 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.50

Get Galapagos alerts:

Galapagos MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 19.5% Upside
$34.50 Price Target
Short Interest: Bearish
2.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.50
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.20) to $0.06 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.53 out of 5 stars

Medical Sector

869th out of 918 stocks

Pharmaceutical Preparations Industry

399th out of 424 stocks

2.0

Analyst's Opinion

Consensus Rating
Galapagos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Galapagos has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.18% of the float of Galapagos has been sold short.
Short Interest Ratio / Days to Cover
Galapagos has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Galapagos has recently decreased by 2.74%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Galapagos does not currently pay a dividend.
Dividend Growth
Galapagos does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLPG.

1.9

News and Social Media Coverage

News Sentiment
Galapagos has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Galapagos this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for GLPG on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added Galapagos to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galapagos insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.91% of the stock of Galapagos is held by insiders.
Percentage Held by Institutions
Only 32.46% of the stock of Galapagos is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Galapagos are expected to grow in the coming year, from ($0.20) to $0.06 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galapagos is -12.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galapagos is -12.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galapagos has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Galapagos Stock (NASDAQ:GLPG)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

GLPG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLPG Stock News Headlines

April 18, 2024 | americanbankingnews.com

Galapagos (NASDAQ:GLPG) Reaches New 52-Week Low at $29.45

April 12, 2024 | americanbankingnews.com

Galapagos (NASDAQ:GLPG) Sets New 12-Month Low at $31.22

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 9, 2024 | americanbankingnews.com

Galapagos NV (NASDAQ:GLPG) Given Average Recommendation of "Hold" by Analysts

April 4, 2024 | globenewswire.com

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

April 1, 2024 | msn.com

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst

April 1, 2024 | finance.yahoo.com

Galapagos Full Year 2023 Earnings: Beats Expectations

March 28, 2024 | finanznachrichten.de

Galapagos NV: Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 28, 2024 | finance.yahoo.com

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

March 28, 2024 | globenewswire.com

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

March 28, 2024 | finanznachrichten.de

Galapagos NV: Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

March 28, 2024 | msn.com

BofA downgrades Galapagos to Underperform over lack of catalysts in the near term

March 26, 2024 | globenewswire.com

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

March 20, 2024 | nasdaq.com

Galapagos Enters Oversold Territory (GLPG)

March 16, 2024 | finance.yahoo.com

GLPG Oct 2024 45.000 put

March 16, 2024 | finance.yahoo.com

GLPG Apr 2024 42.500 put

March 7, 2024 | seekingalpha.com

Galapagos: Pipeline Still Progressing Despite Financial Volatility

March 7, 2024 | realmoney.thestreet.com

Galapagos assumed with an Equal Weight at Morgan Stanley

March 3, 2024 | finance.yahoo.com

GLPG Mar 2024 32.500 put

February 27, 2024 | realmoney.thestreet.com

Galapagos price target lowered by EUR 4 at Barclays

February 27, 2024 | markets.businessinsider.com

Galapagos (GLPG) Gets a Hold from RBC Capital

February 26, 2024 | finance.yahoo.com

GLPG Mar 2024 37.500 put

February 24, 2024 | finance.yahoo.com

Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript

February 22, 2024 | globenewswire.com

Galapagos announces full year 2023 results and outlook for 2024

February 21, 2024 | msn.com

Galapagos FY 2023 Earnings Preview

February 19, 2024 | finance.yahoo.com

GLPG Mar 2024 40.000 call

See More Headlines

Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GLPG
CUSIP: N/A
CIK: 1421876
Web: www.glpg.com
Phone: (321) 534-2900
Fax: 321-534-2901
Employees: 1,123
Year Founded: 1999

Price Target and Rating

Average Stock Price Target: $34.50
High Stock Price Target: $38.00
Low Stock Price Target: $31.00
Potential Upside/Downside: +19.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $229.12 million
Net Margins: -26.25%
Pretax Margin: 2.35%
Return on Equity: -2.60%
Return on Assets: -1.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.02
Quick Ratio: 8.84

Sales & Book Value

Annual Sales: $259.40 million
Price / Sales: 7.34
Cash Flow: $0.64 per share
Price / Cash Flow: 45.29
Book Value: $45.92 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 65,900,000
Free Float: 63,979,000
Market Cap: $1.91 billion
Optionable: Optionable
Beta: 0.24

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Paulus A. Stoffels M.D. (Age 62)
Ph.D., CEO, Chairman, Interim Head of R&D
Comp: $974.86k
Mr. Thad Huston (Age 54)
CFO & COO
Ms. Sofie Van Gijsel
Head of Investor Relations
Ms. Valeria Cnossen
General Counsel
Marieke Vermeersch
Head of Corporate Communication
Ms. Annelies Missotten
Chief Human Resources Officer
Ms. Ellen Van Der Aar
Head of Development
Mr. Philippe Alen M.B.A.
Ph.D., Pharm.D., Senior VP & Head of Business Development
Mr. Dirk De Naeyer
Head of Development Operations
Ms. Alice Dietrich
Head of Medical Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GLPG Stock Analysis - Frequently Asked Questions

Should I buy or sell Galapagos stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings or view top-rated stocks.
What is Galapagos' stock price target for 2024?: 5 analysts have issued 12-month target prices for Galapagos' stock. Their GLPG share price targets range from $31.00 to $38.00. On average, they predict the company's stock price to reach $34.50 in the next year. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts.
How have GLPG shares performed in 2024?: Galapagos' stock was trading at $40.65 at the beginning of 2024. Since then, GLPG stock has decreased by 29.0% and is now trading at $28.86.
View the best growth stocks for 2024 here.
When is Galapagos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GLPG earnings forecast.
What ETFs hold Galapagos' stock?: ETFs with the largest weight of Galapagos (NASDAQ:GLPG) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).ERShares NextGen Entrepreneurs ETF (ERSX).
What is Onno van de Stolpe's approval rating as Galapagos' CEO?: 6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).
When did Galapagos IPO?: Galapagos (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.
Who are Galapagos' major shareholders?: Galapagos' stock is owned by a variety of retail and institutional investors. Top institutional investors include GAMMA Investing LLC (0.00%).
How do I buy shares of Galapagos?: Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLPG) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galapagos (GLPG) Stock Price, News & Analysis

Galapagos MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Galapagos Stock (NASDAQ:GLPG)

GLPG Stock Price History

GLPG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

GLPG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™